Petros Pharmaceuticals, Inc. is focused on the self-care market by providing expanded access to key prescription pharmaceuticals such as OTC treatment options. The Company is engaged in developing a software-as-a-service (SaaS) platform designed to assist pharmaceutical companies in meeting FDA standards to assist in the Rx-to-OTC switch. In addition to the SaaS component, the platform is intended to incorporate software as a medical device (SaMD) capabilities, transforming traditional OTC medications into digitally enabled solutions. The SaMD interface seeks to be designed as customized and branded to pharmaceutical therapy and established as a specific application pathway to that therapy. Together, it aims to develop the SaaS and SaMD components to create a scalable, licensable platform that supports various classes of medications across the pharmaceutical industry, assisting pharmaceutical companies achieve regulatory approval, while delivering consumer-focused healthcare solutions.
Unternehmens-codePTPI
Name des UnternehmensPetros Pharmaceuticals Inc
IPO-datumDec 02, 2020
Gegründet am2020
CEO- -
Anzahl der mitarbeiter18
WertpapierartOrdinary Share
GeschäftsjahresendeDec 02
Addresse1185 Avenue Of The Americas, 3Rd Floor
StadtNEW YORK
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl10036
Telefon19732420005
Websitehttps://www.petrospharma.com/
Unternehmens-codePTPI
IPO-datumDec 02, 2020
Gegründet am2020
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten